Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
Sequential BRII-179 treatment produced HBsAg loss rates above 40%, while the concurrent triple regimen did not beat historical comparators, Brii Bio said.
- On Thursday, Brii Biosciences Limited announced Phase 2b results from its ENRICH and ENHANCE studies evaluating BRII-179 combination regimens for chronic HBV infection.
- The studies aimed to select optimal combination regimens, with ENRICH evaluating BRII-179 as priming therapy prior to elebsiran and PEG-IFN, while ENHANCE tested concurrent triple combination.
- ENRICH demonstrated HBsAg loss rates of 42.9% and 40.0% across two dosing schedules, while ENHANCE's concurrent triple combination achieved 25.5% compared to 29.7% in ENSURE cohorts.
- Chief Medical Officer Dr. David Margolis noted the ENRICH design is "preferred for a registrational study," with Brii Biosciences Limited planning to present detailed data later this year.
- Advancement of ENRICH into Phase 3 remains subject to arbitration with Vir Biotechnology regarding elebsiran manufacturing, leaving the program's future uncertain until claims are resolved.
37 Articles
37 Articles
The Berkshire Eagle
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategiesEnd-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ENSURE…
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B - PressReach
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies End-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ENSURE Cohorts 2 and 3, informing selection of combination regimen going forward As previously disclosed, advancement of ENRICH into Phase 3 remains subject to …
Brii Bio Phase 2b hepatitis B data from ENRICH and ENHANCE studies released
DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-treatment (EOT) results from its ongoing Phase 2b ENRICH and ENHANCE studies investigating sequential versus concurrent combination regimens of BRII-179 with elebsira…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
